Servier's Protelos and Osseor are still important despite VTE and skin concerns, says EMA
This article was originally published in Scrip
Executive Summary
Servier's bone drugs, Protelos and Osseor (strontium ranelate) is still an "important treatment" for women with osteoporosis, says the European Medicines Agency. The drugs' benefit: risk profile remains favourable, but the medicine is no longer to be recommended for certain patients, while warnings on serious skin reaction are to be updated.